TNFRSF18 and neoplasm: Similar to 4-1BB, targeting OX40 or GITR has been shown to stimulate robust anti-tumor responses in several pre-clinical tumor models, through a similar mechanism of action i.e. agonizing effector T cells or depleting Tregs (81–83).